healthcare
Wegovy-Maker Novo Nordisk Starts 'fight Back' as Investors Return
Doctors Without Borders Voices Outrage Over Death of Its Nurse From Israeli Airstrike
FinanceH.I.G. Portfolio Company Iron Bow Divests Telehealth Unit in Strategic Sale
Lilly Sees Obesity Drug Leadership Beyond US as It Leans on Consumer-Focused Strategy
Lilly Gets a Boost From New Weight-Loss Pill Data as It Weighs Speedier Approval in US
Date: September 17, 2025
VIENNA (Reuters) - Eli Lilly's international president said on Wednesday it was too early to assume the company would use the U.S. Food and Drug Administration's new fast-track review process for its...
AstraZeneca's Asthma Drug Fails 'smoker's Lung' Study
Date: September 17, 2025
(Reuters) - AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic obstructive pulmonary disease (COPD) in a late-stage study, in a...
UK Must Spend More on Medicines, Minister Says, as Big Pharma Cuts Investment
Date: September 16, 2025
By Alistair Smout LONDON (Reuters) -Britain needs to reverse its declining spend on medicines, science minister Patrick Vallance said on Tuesday, after two major pharmaceutical firms cancelled or...
Lilly Weight-Loss Pill Could Be FDA-approved by Year-End
Date: September 16, 2025
By Deena Beasley (Reuters) -Eli Lilly's experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several...
Australia's Csl Invests $117 Million for VarmX Acquisition Option, Coagulation Treatment
Date: September 16, 2025
(Reuters) -Australia's CSL said on Tuesday it will pay $117 million upfront to Dutch firm VarmX for an exclusive option to acquire the privately held company and advance the development of a blood...
US Tariffs, Pricing Risks to Be Manageable for Big Pharma, Morningstar Says
Date: September 10, 2025
(Reuters) -The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European...